Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer (Q33400687)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer |
scientific article |
Statements
1 reference
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer (English)
1 reference
Glen J Weiss
1 reference
Ross C Donehower
1 reference
Tara Iyengar
1 reference
Ramesh K Ramanathan
1 reference
Karen Lewandowski
1 reference
Eric Westin
1 reference
Karla Hurt
1 reference
Scott M Hynes
1 reference
Stephen P Anthony
1 reference
Scott McKane
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference